TAK 004
Alternative Names: TAK-004Latest Information Update: 16 Feb 2024
At a glance
- Originator Takeda
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 01 Feb 2024 Preclinical trials in Unspecified in Japan before February 2024 (unspecified route)
- 01 Feb 2024 Takeda plans a first-in-human phase I trial (In volunteers) (SC) (NCT06236009)